Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18798943 | 1.00 | SLC6A2 (0.30) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17427854 | 1.00 | SLC6A2 (0.30) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18574583 | 0.86 | SLC6A2 (0.32) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25492728 | 0.81 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19174820 | 0.81 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19432816 | 0.75 | SIGMAR1 (0.35) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19398850 | 0.75 | ALDH1A1 (0.30) | — | |
| SCHEMBL18798712 | 0.75 | — | — | |
| SCHEMBL18798927 | 0.71 | — | — | |
| SCHEMBL1922253 | 0.67 | MAPK1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834447-B2 | Indole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2023-12-05 | — | — | US | disclosed |
| US-10196364-B2 | Pyrimidine carboxamides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10012650-B2 | Assays for BTK inhibitors | MERCK PATENT GMBH (DE) | 2018-07-03 | — | — | US | disclosed |
| US-10005768-B2 | Carboxamide derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10000475-B2 | Triazine carboxamides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20180134690-A1 | INDAZOLES AND USE THEREOF | PURDUE PHARMA LP (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134707-A1 | AZASPIRO[4.5]DECANE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2018-05-17 | — | — | US | disclosed |
| US-9884865-B2 | Azaspiro[4.5] decane derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9834543-B2 | Indazoles and use thereof | PURDUE PHARMA L.P. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170283392-A1 | DIBENZAZEPINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2017-10-05 | — | — | US | disclosed |
| US-20160169894-A1 | ASSAYS FOR BTK INHIBITORS | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
| US-9359330-B2 | Substituted piperidines as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160031873-A1 | Carboxamide Derivatives and Use Thereof | PURDUE PHARMA L.P. | 2016-02-04 | — | — | US | disclosed |
| US-20160009659-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2016-01-14 | — | — | US | disclosed |
| US-20150353512-A1 | TRIAZINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-12-10 | — | — | US | disclosed |
| US-20150284383-A1 | INDOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2015-10-08 | — | — | US | disclosed |
| US-9120786-B2 | Triazine carboxamides as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150175569-A1 | DIBENZAZEPINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2015-06-25 | — | — | US | disclosed |
| US-20150057300-A1 | SUBSTITUTED PIPERIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-02-26 | — | — | US | disclosed |
| US-20140249128-A1 | TRIAZINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196364-B2 | Pyrimidine carboxamides as sodium channel blockers | CACNA1A, TRPV1, TRPA1 | SLC6A2 180/4885SLC6A4 135/4885SLC6A3 235/4885 |
| US-20180134707-A1 | AZASPIRO[4.5]DECANE DERIVATIVES AND USE THEREOF | TRPV1, SCN5A, TRPA1 | SLC6A2 627/4885SLC6A4 688/4885SLC6A3 419/4885 |
| US-11834447-B2 | Indole derivatives and use thereof | TRPC4, TRPV4, TRPV1 | SLC6A2 164/4885SLC6A4 8/4885SLC6A3 143/4885 |
| US-20170283392-A1 | DIBENZAZEPINE DERIVATIVES AND USE THEREOF | CACNA1A, CACNA1D, CACNA1S | SLC6A2 383/4885SLC6A4 250/4885SLC6A3 119/4885 |
| US-20160169894-A1 | ASSAYS FOR BTK INHIBITORS | BTK, SYK, LYN | SLC6A2 4679/4885SLC6A4 4683/4885SLC6A3 4617/4885 |
| US-20150175569-A1 | DIBENZAZEPINE DERIVATIVES AND USE THEREOF | CACNA1A, CACNA1D, CACNA1S | SLC6A2 383/4885SLC6A4 250/4885SLC6A3 119/4885 |
| US-10005768-B2 | Carboxamide derivatives and use thereof | TRPV1, CACNA1A, SCN10A | SLC6A2 406/4885SLC6A4 185/4885SLC6A3 710/4885 |
| US-20160031873-A1 | Carboxamide Derivatives and Use Thereof | TRPV1, CACNA1A, SCN10A | SLC6A2 740/4885SLC6A4 348/4885SLC6A3 1592/4885 |
| US-20140249128-A1 | TRIAZINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | TRPV1, SCN2A, SCN2B | SLC6A2 109/4885SLC6A4 123/4885SLC6A3 259/4885 |
| US-20150353512-A1 | TRIAZINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | TRPV1, SCN2A, SCN2B | SLC6A2 109/4885SLC6A4 123/4885SLC6A3 259/4885 |
| US-10000475-B2 | Triazine carboxamides as sodium channel blockers | TRPV1, SCN2A, SCN2B | SLC6A2 109/4885SLC6A4 123/4885SLC6A3 259/4885 |
| US-10012650-B2 | Assays for BTK inhibitors | BTK, SYK, LYN | SLC6A2 4679/4885SLC6A4 4683/4885SLC6A3 4617/4885 |
| US-20150284383-A1 | INDOLE DERIVATIVES AND USE THEREOF | TRPC4, TRPV4, TRPV1 | SLC6A2 164/4885SLC6A4 8/4885SLC6A3 143/4885 |
| US-20180134690-A1 | INDAZOLES AND USE THEREOF | TRPV3, TRPA1, TRPV1 | SLC6A2 486/4885SLC6A4 239/4885SLC6A3 248/4885 |
| US-20160009659-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | CACNA1A, TRPV1, TRPA1 | SLC6A2 175/4885SLC6A4 137/4885SLC6A3 241/4885 |
| US-20150057300-A1 | SUBSTITUTED PIPERIDINES AS SODIUM CHANNEL BLOCKERS | CACNA1A, SCN1B, CACNA1E | SLC6A2 165/4885SLC6A4 158/4885SLC6A3 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.